Despite these cautions on use of NfL as a longitudinal biomarker of neurodegeneration in AD clinical trials targeting tau pathology, it is encouraging that plasma NfL concentration changes in response to tau-directed therapeutic intervention. The gene discussed is MAPT; the disease is Alzheimer disease.